Purchase this article with an account.
Young Ju Lew, Jungil Han, Han Joo Cho, Jae Hui Kim; Intravitreal Anti-Vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Cluster. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3891.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate outcomes after 12 months of anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV) with grape-like polyp clusters. Outcomes were compared to those in eyes with PCV and no clusters.
This retrospective, observational study included 20 eyes with PCV with grape-like polyp clusters and 29 eyes with PCV without clusters. All patients underwent three intravitreal ranibizumab injections as an initial treatment. Additional injections were performed when exudation recurrence was suspected. Best-corrected visual acuity (BCVA) at diagnosis and 6 and 12 months into therapy were compared within each group.
Baseline, 6 month, and 12 month logarithm of minimal angle of resolution (logMAR) BCVA in cluster PCV was 0.63 ± 0.37, 0.49 ± 0.43, and 0.54 ± 0.48, respectively. Compared to baseline, BCVA was significantly better at 6 months (P = 0.011) but not at 12 months (P = 0.388). In eyes with PCV and no clusters, logMAR BCVA at baseline, 6 months, and 12 months was 0.59 ± 0.32, 0.49 ± 0.32, and 0.51 ± 0.31, respectively. The BCVA was significantly better than at baseline at both 6 (P = 0.002) and 12 months (P = 0.037).
Although anti-VEGF therapy had favorable short-term efficacy in treating PCV with grape-like polyp clusters, long-term visual improvements were limited. Appropriate treatment strategies for this peculiar condition are needed.
This PDF is available to Subscribers Only